April 5, 2016
Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced the launch of Xadago (safinamide) in Belgium for the treatment of mid- to late-stage Parkinson’s disease (PD). Following the launch in Switzerland, Germany, Spain and Italy, Xadago (safinamide) is now available in Belgium as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD therapies for mid-to late-stage fluctuating patients.
Safinamide is a new chemical entity with a dopaminergic and non-dopaminergic action, providing a balanced control of motor symptoms and motor complications.
Prof. Patrick Santens, from University Hospital Ghent commented: “Thanks to its unique dual dopaminergic and non-dopaminergic mode of action, including the modulation of altered glutamatergic neurotransmission, Xadago (safinamide) has the potential to become a long awaited treatment alternative for our patients suffering from idiopathic Parkinson’s disease with motor fluctuations.”
Maurizio Castorina, CEO of Zambon SpA said: “We are glad to see health authorities across Europe approving the reimbursement of Xadago (safinamide) for PD patients. Patients in Belgium will now have access to an innovative add-on treatment option that has shown meaningful and long lasting improvements on motor symptomsand good ON Time without troublesome dyskinesia, in addition to a well-tolerated profile.”
http://www.pharmpro.com/news/2016/04/zambon-launches-safinamide-patients-mid-late-stage-parkinsons
No comments:
Post a Comment